Leukocyte adhesion deficiency-1 (LAD-1), a genetic immunodeficiency disease characterized by life-threatening bacterial infections, results from the defective adherence and migration of leukocytes due to mutations in the leukocyte integrin CD18 molecule. Canine LAD (CLAD) represents the canine homologue of the severe phenotype of LAD-1 in children. In previous studies we demonstrated that non-myeloablative stem cell transplantation from matched littermates resulted in mixed donor-host chimerism and reversal of the disease phenotype in CLAD. In this study, we describe two CLAD dogs with less than 2% donor leukocyte chimerism following non-myeloablative transplant. Both dogs are alive more than 24 months after transplant with an attenuated CLAD phenotype resembling the moderate deficiency phenotype of LAD. The improvement in the CLAD phenotype with very low levels of donor CD18 þ leukocytes correlated with the preferential egress of the CD18 þ neutrophils into extravascular sites. The clinical response with very low levels of donor CD18 þ leukocytes in CLAD supports using this model for testing gene therapy strategies since the low levels of gene-corrected hematopoietic cells expected with hematopoietic gene therapy would likely have a therapeutic effect in CLAD.
Introduction
Leukocyte adhesion deficiency type 1 (LAD-1) is an autosomal recessive genetic immunodeficiency disease in humans that was first described in the 1970s. 1 Typical clinical features in severe deficiency LAD-1 patients include omphalitis, necrotic infections of soft tissues, chronic gingivitis, periodontitis and impaired wound healing. 2 Infections frequently result in death in children with severe deficiency LAD-1. 2 Heterogenous molecular defects in the leukocyte integrin CD18 are responsible for LAD-1. These molecular defects result in the absence, or markedly reduced, expression of the CD11/CD18 complex on the leukocyte surface. 3 LAD leukocytes display markedly impaired adhesion to the blood vessel wall and impaired migration to sites of infection as a result of the inability to express CD18. 4 The severity of infectious complications among LAD-1 patients is directly related to the percentage of CD18 expression on the leukocytes. 5 LAD-1 patients can be categorized as moderate or severe phenotype according to the quantitative expression of CD18 on the leukocyte surface. 2 Moderate deficiency LAD-1 children express 1-10% of normal level of CD18 and frequently survive into adulthood. 6 In contrast, severe deficiency LAD-1 children express o1% CD18 expression on their leukocytes. Approximately 75% of these children die before 2 years of age due to bacterial infection. 2 Current definitive treatment for LAD-1 patients involves a pretransplant myeloablative conditioning regimen followed by allogeneic hematopoietic stem cell transplant. 7, 8 This regimen is designed to result in full donor chimerism. However, in one study of allogeneic stem cell transplant for LAD-1, several patients developed mixed chimerism following transplant despite receiving a myeoablative conditioning regimen. 9 All four of these individuals had reversal of the disease phenotype, indicating that full donor chimerism is not required for the correction of the LAD-1 phenotype.
In the mid-1970s, a disease resembling the severe phenotype of LAD-1 was described in Irish Setter dogs. This disease was later recognized as canine LAD (CLAD). 10, 11 CLAD-affected dogs, like humans with LAD, develop recurrent, life-threatening bacterial infections starting at birth. The infectious complications usually lead to death or euthanasia by 6 months of age.
12,13 CLAD results from a point mutation in a highly conserved cysteine residue of the canine CD18 molecule, which leads to the failure to express the CD11/CD18 adhesion complex on the leukocyte surface. 14 We established a CLAD colony and utilized CLAD as a disease-specific, large animal model to test potential hematopoietic stem cell therapeutic approaches. 12 Our previous study of 13 allogeneic transplants in CLAD dogs demonstrated that matched littermate hematopoietic stem cell transplant following a non-myeloablative conditioning regimen resulted in correction of the CLAD phenotype with mixed donor chimerism without graft-versus-host disease (GVHD). 15 Moreover, even a level of donor chimerism of 5-10% was shown to reverse the disease phenotype. 16 In this study, we describe the long-term survival of two CLAD dogs with donor microchimerism (o2% donor CD18 þ leukocytes) following a non-myeloablative hematopoietic stem cell transplant. In both dogs the phenotype following transplant resembled the moderate phenotype of LAD-1 in which the patients express 1-10% of normal levels of CD18 expression and have a milder disease phenotype. The observation that low levels of CD18 þ leukocytes are beneficial in CLAD supports the testing of gene therapy strategies in this model since low numbers of CD18
þ leukocytes are anticipated with current gene therapy vectors and transduction conditions.
Materials and methods

Dogs
Dogs were housed in facilities on the campus of the National Institutes of Health (NIH) in Bethesda, MD, USA, in accordance with NIH guidelines. The facilities are approved by the American Association for Accreditation of Laboratory Animal Care (AAALAC). Animal study protocols were approved by the Institutional Animal Care and Use Committee of the National Cancer Institute, Bethesda, MD, USA. Dogs were vaccinated for common infectious diseases. CLAD dogs used in this study resulted from the breeding of either two CLAD heterozygotes (Spock, D128) or the breeding of a CLAD heterozygote with a CLAD dog previously treated by bone marrow transplant (Billie, D144).
Monitoring of CLAD dogs CLAD dogs were evaluated daily by physical examination. All CLAD dogs were treated with prophylactic oral antibiotics starting at birth. If fever or infections persisted beyond 48 h after the initiation of oral antibiotics, treatment with parental antibiotics was started.
White blood cell (WBC) counts and differentials were carried out at a commercial laboratory (Antech Diagnostics, Lack Success, NY, USA) or at the NIH. WBC were measured prior to transplant and at designated time points post transplant. Routine serum chemistries were performed prior to and following transplantation.
Bone marrow harvest and transplantation
Matched littermate donor-recipient pairs were chosen using highly polymorphic microsatellite markers in the dog leukocyte antigen (DLA) loci as previously described. 12, 17 Both dogs were transplanted following non-myeloablative conditioning regimens. The first CLAD dog (Spock, designated D128) received total body irradiation (TBI) at a dose of 200 cGy delivered from a 60 Co source 4 h prior to the infusion of donor peripheral blood stem cells (PBSC) on the day of transplantation (day 0). The second CLAD dog (Billie, designated D144) received 10 mg/kg busulfan administered intravenously 48 h prior to allogeneic bone marrow transplant.
The hematopoietic stem cell source differed in the two dogs. The first CLAD dog (D128) received PBSC, and second CLAD dog (D144) received bone marrow hematopoietic stem cells. In CLAD dog D128, PBSC were collected from the matched littermate donor by apheresis. PBSC were mobilized using recombinant canine granulocyte colonystimulating factor at 20 mg/kg/day and recombinant canine stem cell factor at 50 mg/kg/day administered subcutaneously for 5 days. On the 5th day, apheresis was performed with a CS3000 Plus Blood Cell Separator (Fenwal Division, Baxter Healthcare, Deerfield, IL, USA) using a modification of a previously described procedure. 18 In the second CLAD dog D144, bone marrow cells were isolated according to a previously described procedure. 19 In both cases the donor hematopoietic stem cells were infused intravenously into the recipient on the day of transplant. Aliquots of both the PBSC and the bone marrow harvest were analyzed to determine the dose of CD34 þ cells in the donor sample. The post transplant immunosuppression regimen consisted of cyclosporine A (CSP) (Sandimmune, Novartis, East Hanover, NJ, USA) and mycophenolate mofetil (MMF) (CellCept, Roche, Nutley, NJ, USA). Recipient CLAD dogs received 15 mg/kg CSP orally twice daily starting on day À1, and continuing until day 35. From days 36 to 65, CSP was given orally twice daily at a dose of 7.5 mg/kg. MMF was given orally at a dose of 10 mg/kg twice daily from days 0 until 28.
Donor lymphocyte infusion (DLI)
In addition to the PBSC, CLAD dog D128 received a total of four DLI starting 6.5 months after transplant, and administered at approximately 1 month intervals. The unsensitized DLI consisted of 2.2 Â 10 6 , 24 Â 10 6 , 10 Â 10 6 and 16.7 Â 10 6 CD34 þ cells per kilogram body weight, respectively. Cells for DLI were obtained by overlaying peripheral blood on NycoPrep 1.077A (Griener bio-Onc, Longwood, FL, USA), then centrifuged at 800 g for 15 min at room temperature. Cells were collected and washed with saline along with heat-inactivated autologous canine serum and 5 U/ml heparin. Before infusion, the percentage of CD34 þ content of the product was analyzed using flow cytometry (FACS Calibur, Becton Dickison, San Jose, CA, USA). Unconjugated CD3 antibody was labeled with a Zenon R-PE mouse IgG1 labeling kit (Molecular Probes, Eugene, OR, USA) according to the manufacture's directions.
Assessment of donor chimerism by flow cytometry
Peripheral blood leukocytes and bone marrow cells were collected from the recipient at designated time points and Donor microchimerism moderates the CLAD phenotype Y-C Gu et al analyzed by flow cytometry for expression of CD18 on the cell surface. Red blood cells were removed by lysis, and the leukocytes were stained with a FITC-conjugated mouse anti-human CD18 monoclonal antibody (MHM23; DakoCytomation, Carpinteria, CA, USA) that crossreacts with canine CD18 molecule. 19, 20 Leukocyte subset chimerism was determined by co-staining of CD18 with subset-specific antibodies as previously described. 16 
Saliva collection
To measure leukocyte emigration into tissues, saliva was collected from both dogs post transplant. The oral cavity was lavaged using 200 cc of saline, and collected into a clean container. The collected mouth lavage was filtered through a 100 mm filter and centrifuged for 15 min at 400 g to form a cell pellet. The cells were then stained with an anti-CD18 monoclonal antibody and analyzed by flow cytometry as described above.
Donor DNA chimerism post transplant DNA microsatellite markers were used to determine the percentage of donor chimerism in peripheral blood, bone marrow and saliva. Informative markers distinguishing donor and host DNA were identified. Marker set FH2263 was used for D144 and marker set FH2141 was used for dog D128. 21 Genomic DNA was extracted with Wizard Genomic DNA Purification kit (Promega, Madison, WI, USA) and subjected to PCR amplification as previously described. 16 PCR products were analyzed on an ABI 3100 Genetic Analyzer. The percentage of donor chimerism was calculated by calculating the area under the donor DNA PCR peaks and dividing this area by the summed areas of the donor and host DNA PCR peaks. (Table 1 ). Prior to transplant each dog received a non-myeloablative conditioning regimen consisting of either 200 cGy of TBI (D128) on the day of transplant or intravenous administration of busulfan at 10 mg/kg 48 h prior to bone marrow transplant (D144). Post transplant immunosuppression consisted of CSP and MMF as previously described. 22 The details of the two CLAD dogs who were transplanted are shown (Table 1) .
Results
Hematopoietic stem cell transplantation
Donor chimerism and engraftment post transplant
Flow cytometric analysis of peripheral blood leukocytes was used to measure the CD18 þ donor-derived cells in the transplanted dogs. Pretransplant flow cytometric analysis confirmed the absence of CD18 þ cells in the peripheral blood of both CLAD dogs (Figure 1a and b, pre) . At 1 month post transplant the level of donor-derived, CD18 þ leukocytes in the peripheral blood of the two transplanted dogs was 1.84% (D128) and 2.52% (D144), respectively ( Figure 1a and b, 1 M post) . The levels then declined over the ensuring months and remained at very low levels in the peripheral blood for 2 years.
In an attempt to boost the donor leukocyte chimerism, CLAD dog D128 received a total of four DLIs between days 197 and 307 post transplant with doses ranging from 2.2 Â 10 6 to 24 Â 10 6 CD34 þ cells per kilogram body weight (Table 1) . Despite the DLI, the level of donor CD18 þ leukocytes increased only slightly over the ensuring months (Figure 1c) . At 24 months after transplant the levels of CD18 þ donor-derived leukocytes in the two dogs were 1.68% (D128) and 0.64% (D144), respectively ( Figure 1a, b  and c) .
The contribution of each leukocyte subset to the total chimerism was determined by co-staining the recipient peripheral blood leukocytes with lineage-specific antibodies to distinguish CD34 þ T cells, neutrophils and monocytes. The percentage of cells staining for CD18 in each subset is shown (Figure 2 ). In both dogs the level of donor CD18 þ neutrophils and monocytes parallelled each other, however, the level of myeloid chimerism remained significantly lower than the level of lymphoid chimerism. In the case of D128, starting at 1.5 months post transplant donor-derived myeloid cells were at an average of 0.15% donor CD18 þ neutrophils and 0.56% donor CD18 þ monocytes, respectively. The percentage of CD18 þ donor lymphocytes on average was 8.65%. Similar split chimerism was also seen in D144 with four times greater lymphoid chimerism than myeloid chimerism.
Clinical phenotype of dogs post transplantation
Both CLAD dogs are alive on prophylactic oral antibiotics more than 2 years post transplant. One of the hallmarks of CLAD disease, an elevated peripheral blood leukocyte (Figure 3a) . This leukocytosis gradually improved and by 2 years post transplant both D128 and D144 displayed WBC counts that were either normal (D144), or slightly higher than normal (D128) (Figure 3a) .
The clinical episodes of fever (X39.41C) prior to and post transplant are depicted (Figure 3b) . Before transplant both dogs demonstrated typical clinical episodes of CLAD disease including skin lesions, fever and hypertrophic osteodystrophy as previously described. 23 Following transplant both dogs had sporadic episodes of fever, however, the frequency of these episodes has progressively decreased with time. In contrast, all CLAD dogs not receiving transplant died or were euthanized due to the intractable infections by 6 months of age. 23 
Peripheral blood absolute neutrophil counts post transplant
The absolute number of neutrophils in the peripheral blood of each CLAD dog post transplant was assessed using CD18 þ neutrophil percentage multiplied by the total neutrophil counts in the peripheral blood (Table 2 ). CLAD dog D128 had less than 100 Â 10 6 CD18 þ neutrophils/l in the peripheral blood on all but one occasion post transplant, and D144 displayed peripheral blood CD18 þ ANC counts consistently less than 10 Â 10 6 CD18 þ neutrophils/l starting at 6 months post transplant.
Analysis of extravasated donor leukocytes into the tissue
To investigate whether the protective effects of the very low levels of CD18 þ leukocytes in the two CLAD dogs might Figure 1 Total donor-derived CD18-positive leukocytes in the peripheral blood prior to and following matched littermate hematopoietic stem cell transplant. Peripheral blood was collected at the designated intervals, leukocytes were isolated and stained with anti-CD18 FITC antibody, and examined by flow cytometry. Cell populations were identified by side scatter (y axis) and CD18 fluorescence intensity (x axis). For both dogs, D128 (a) and D144 (b), the samples were taken before transplant, and 1, 12 and 24 months post transplant. The boxes enclose the leukocytes that are donor-derived CD18-positive cells. The percentage of donor derived CD18-positive leukocytes in the peripheral blood post transplant is depicted over time (x axis) in these two dogs (c).
be due to the selective migration of the CD18 þ leukocytes into the tissue, samples from the bone marrow, peripheral blood, and saliva were collected from each dog at approximately 2 years post transplant. Donor leukocyte chimerism in the peripheral blood and in saliva was assessed by flow cytometric analysis and DNA-based analysis (Figures 4 and 5) . A similar pattern of results was found in each dog. A low percentage of donor chimerism was seen in bone marrow and peripheral blood, whereas a significantly higher percentage of CD18 þ donorderived leukocytes was present in the saliva. Eleven-fold (D128) and five-fold (D144) more donor-derived CD18 þ leukocytes were present in saliva compared to the peripheral blood at 24 and 22 months post transplant, respectively (Figure 4a and b) .
The percentage of donor chimerism was also determined using DNA microsatellite markers ( Figure 5 determined by DNA analysis, whereas 1.68% and 18.9% donor cells present in peripheral blood and saliva, respectively, by flow cytometric analysis (compare Figures  4a and 5 ).
Discussion
We describe two dogs with the genetic immunodeficiency disease CLAD who have shown attenuation of the severe CLAD disease phenotype following matched littermate allogeneic hematopoietic stem cell transplant despite having levels of CD18 þ donor leukocytes of less than 2%. This very low level of donor CD18 þ leukocytes resulted in marked improvement of the clinical condition and the resolution of the leukocytosis in both dogs. Both dogs displayed evidence of preferential extravasation of the CD18 þ leukocytes into the oral cavity, a frequent site of disease in CLAD. This preferential egress of CD18 þ leukocytes from the peripheral blood into the tissue may explain how o2% of donor leukocyte chimerism moderates the CLAD disease phenotype.
Previous studies have shown that mixed donor:recipient hematopoietic chimerism can be achieved in normal DLAmatched littermate transplant using sublethal 200 cGy TBI conditioning and post transplant immunosuppression with MMF and cyclosporine (CSP). 24 This same non-myeloablative conditioning regimen, which was used for dog D128 in this study, has been shown previously by our laboratory to result in mixed hematopoietic chimerism and reversal of the phenotype in CLAD following matched littermate transplant. 15 In that study donor bone marrow, bone marrow CD34 þ cells and PBSC all resulted in engraftment and correction of the CLAD phenotype. 15 Recently, we used single-agent busulfan at 10 mg/kg for conditioning prior to matched littermate bone marrow transplant in CLAD, and also observed engraftment with mixed chimerism and reversal of the CLAD phenotype. 25 The primary goal of the non-myeloablative CLAD transplant studies was to establish stable donor mixed chimerism and reversal of the CLAD phenotype without GVHD. The secondary goal of these studies was to identify the level of donor chimerism that was sufficient to reverse the disease phenotype. Initial results from our CLAD transplant studies indicated that a level of 5-10% donor leukocyte chimerism correlated with an ANC of 250-500 Â 10 6 cells/l of peripheral blood. This level was sufficient for reversal of the CLAD phenotype. 16 The current studies in these two CLAD dogs have established the lowest level at which disease improvement could be seen, since neither dog displayed complete correction of the phenotype.
The very low level of donor leukocyte chimerism in the two animals in this study has several possible explanations. CLAD dog D128 received a very low dose (2.7 Â 10 5
CD34
þ cells/kg) of PBSC, and never had greater than 2% donor leukocytes. CLAD dog D144 received an adequate dose of donor CD34 þ cells (17.1 Â 10 6 CD34 þ cells/kg), and a conditioning regimen previously shown to result in engraftment of matched littermate stem cells, however, DLA typing in dogs is complicated by an approximately 2% chance of crossover in the linkage of the microsatellite markers to the DLA locus. 26 Thus, it is possible that there existed a DLA mismatch between the donor and the recipient.
To determine how o2% donor microchimerism in the peripheral blood resulted in the moderation of the severe disease phenotype of CLAD, we assessed the presence of CD18 þ leukocytes in mucosal tissues. Since more than 400 bacterial species are present in the oral cavity, this constant bacterial presence in mucosal tissues is kept under control in part by a constant influx of neutrophils from surrounding periodontal tissues. The migrating leukocytes in saliva samples are composed of 98-99% neutrophils. 27 Therefore, the oral saliva collection enables a non-invasive measurement of neutrophil tissue delivery.
The emigration of neutrophils from the circulation is a critical step during immune surveillance and inflammatory reactions, and is governed by a coordinated interaction involving a spectrum of adhesion and signal molecules. 28, 29 Among the different molecules, CD18 plays a pivotal role in neutrophil locomotion and the motility of these cells into extravascular sites. CD18 molecules are constitutively expressed at higher levels in circulating neutrophils than other adhesion molecules, such as integrins b1, b3, b4 and b7. 30 In this study, both dogs displayed evidence of preferential egress of CD18 þ donor cells into saliva as shown by FACS analysis. The increased migration of CD18 þ leukocytes into saliva would explain how the low level of donor microchimerism detected in the peripheral blood is effective in attenuating the severe CLAD disease phenotype. It also suggests that measurement of tissue neutrophils provides additional information over measurement of CD18 þ cells in peripheral blood alone. Besides neutrophils, T cells also play an important role to bacterial infection. Although CD8 þ T cells are primarily associated with defense against viral infections, they also combat against intracellular bacterial infections. 31 The subcellular location of pathogens is important for the detection and elimination by host CD4 þ and CD8 þ T cells. In many bacterial infection settings, CD4
þ T cells recognize vacuolar bacteria and CD8 þ T cells defend against cytosolic pathogens.
31
Murine CD8 þ T-cell response to Listeria monocytogenes, Mycobacterium tuberculosis and Salmonella typhimurium has been well documented. 32 Finally, T cells provide indispensible help to B cells in forming antibodies against pathogens, such as bacteria. Antibody-mediated opsonization is important in clearance of pathogens.
The decreased severity of the CLAD disease phenotype and leukocytosis may relate to the T-cell response to bacteria infection in these two transplanted dogs. In both dogs, the decreasing frequency of infections and the gradual resolution of the leukocytosis correlate with gradual increasing donor engraftment, especially by lymphocytes. The percentage of donor chimerism that resulted in attenuation of the CLAD disease phenotype was notable for the split chimerism between lymphoid and myeloid compartments in the peripheral blood; the percentage of CD18 þ CD34 þ lymphoid compartment was consistently higher than that of CD18 þ neutrophils and monocytes. This split chimerism may also be due to the longer life span of the lymphoid cells and/or the selective egress of donor derived CD18 þ neutrophils into the tissue. The attenuation of the severe CLAD disease phenotype with less than 2% donor chimerism in the two dogs in this report suggest that measurement of tissue neutrophils provides additional evidence compared to measuring CD18 þ leukocytes in the peripheral blood alone. The results also set the stage for the treatment of CLAD by gene therapy where a low number of gene-corrected cells is anticipated with current gene therapy vectors and transduction conditions.
